What are the potential interactions between Pentasa (mesalamine) and colchicine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Mesalamine (Pentasa) and colchicine can be taken together, but patients should be closely monitored for potential side effects, particularly gastrointestinal issues and nephrotoxicity, as both drugs can affect kidney function and cause diarrhea, nausea, and abdominal discomfort 1. When considering the concurrent use of these medications, it's essential to weigh the benefits against the potential risks. The primary concerns include:

  • Additive gastrointestinal side effects, such as diarrhea, nausea, and abdominal pain, which can be managed with adequate hydration and monitoring 1.
  • Theoretical risk of increased nephrotoxicity, as both mesalamine and colchicine can individually affect kidney function, emphasizing the need for periodic blood tests to monitor renal function 1.
  • No significant pharmacokinetic interactions through liver enzyme metabolism have been noted, suggesting that dose adjustments are not typically required based on metabolic interactions alone 1. However, patients with inflammatory bowel disease treated with mesalamine who also require colchicine for conditions like gout or familial Mediterranean fever should have their treatment closely managed by their healthcare provider to mitigate potential adverse effects 1.

From the Research

Potential Interactions between Pentasa (Mesalamine) and Colchicine

There is limited information available on the specific interactions between Pentasa (mesalamine) and colchicine. However, some general information on drug-drug interactions and the properties of mesalamine can be considered:

  • Drug-drug interactions can occur through various mechanisms, including pharmacodynamic and pharmacokinetic interactions, which can lead to adverse drug events 2.
  • Mesalamine is a 5-aminosalicylic acid compound used to treat ulcerative colitis, and it has been shown to be effective in inducing and maintaining clinical remission in patients with mild-to-moderate disease 3, 4, 5.
  • The potential for interactions between mesalamine and other drugs, including colchicine, may depend on various factors, such as the specific formulation of mesalamine, the dose and duration of treatment, and the individual patient's characteristics.
  • Colchicine is a medication used to treat gout and other conditions, and it can interact with various drugs, including those that affect its metabolism or increase the risk of toxicity.
  • However, there is no specific information available on the interactions between Pentasa (mesalamine) and colchicine in the provided studies.

Mechanisms of Drug-Drug Interactions

Some common mechanisms of drug-drug interactions include:

  • Alterations in drug metabolism through interactions with cytochrome P450 enzymes 2.
  • Interactions with P-glycoproteins, which can affect drug absorption and distribution 2.
  • Additive effects, such as increased risk of seizures, QT interval prolongation, central nervous system depression, or serotonin syndrome 2.

Clinical Considerations

When considering the potential interactions between Pentasa (mesalamine) and colchicine, it is essential to:

  • Evaluate the individual patient's characteristics, medical history, and concomitant medications.
  • Monitor for potential adverse effects, such as increased risk of toxicity or reduced efficacy of either drug.
  • Consult drug interaction software and collaborate with pharmacists to optimize drug safety and minimize the risk of adverse drug events 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Mesalamine in the Initial Therapy of Ulcerative Colitis.

Gastroenterology clinics of North America, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.